

Here is a selection of products on mental health produced by CADTH. These and other CADTH products are open access and available at [www.cadth.ca/reports](http://www.cadth.ca/reports). For more information, please contact [requests@cadth.ca](mailto:requests@cadth.ca). The inclusion of reports on particular drugs or other health technologies in this list does not indicate that CADTH endorses these technologies.

### Anxiety and Depressive Disorders

- Addressing Psychological Trauma Due to the COVID-19 Pandemic: Can Technology Help in a Time of Acute Crisis? (*Webinar*, June 2020)
- Internet-Delivered Cognitive Behavioural Therapy (iCBT) Programs for Major Depression and Anxiety Disorders in Canada (*Tool*, Apr. 2020)
- Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis (*Technology Review*, Feb. 2020)
- Internet-Delivered, Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders (*Optimal Use Project*, Mar. 2019)
- Psychotherapy and Pharmacotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Rapid Qualitative Review (*Summary With Critical Appraisal*, Mar. 2020)
- Pharmacogenomic Testing in Depression: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (*Summary With Critical Appraisal*, Feb. 2020)

### Post-Traumatic Stress Disorder

- Post-Traumatic Stress Disorder: Summary of Evidence of the Clinical Effectiveness of Treatments (*Tool*, Apr. 2018)
- Internet-Based Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder (*Optimal Use Project*, Jan. 2020)

### Psychiatric Conditions

- Clozapine Initiation for Schizophrenia: A Review of Clinical Effectiveness and Guidelines (*Summary With Critical Appraisal*, Feb. 2020)
- Ketamine for Pharmacological Management of Aggression and Agitation in Pre-Hospital Settings: A Review of Comparative Clinical Effectiveness, Safety, and Guidelines (*Summary With Critical Appraisal*, May 2019)
- Clonidine for the Treatment of Psychiatric Conditions and Symptoms: A Review of Clinical Effectiveness, Safety, and Guidelines (*Summary With Critical Appraisal*, Feb. 2018)
- Virtual Health Care for Adults With Schizophrenia and/or Psychosis: Clinical Effectiveness and Guidelines (*Reference List*, Sept. 2020)

### Other

- Dialectical Behaviour Therapy for People With Borderline Personality Disorder: A Rapid Qualitative Review (*Summary With Critical Appraisal*, Nov. 2020)
- Lurasidone Hydrochloride for Bipolar Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (*Summary With Critical Appraisal*, Feb. 2020)
- Patient Navigation Programs for People With Dementia: Clinical Utility, Cost-Effectiveness, and Guidelines (*Summary of Abstracts*, Dec. 2020)
- Peer Support for Youth Mental Health: Clinical Effectiveness and Guidelines (*Reference List*, Jan. 2021)

---

CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.

CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Voici un aperçu des produits de l'ACMTS au sujet de la santé mentale. Les documents dont le titre est en anglais ne sont pas disponibles en français. Ces produits de l'ACMTS et tant d'autres sont libres d'accès et disponibles à [www.acmts.ca/rapports](http://www.acmts.ca/rapports). Pour plus d'informations, veuillez contacter [demandes@cadth.ca](mailto:demandes@cadth.ca). Le fait d'inclure des rapports au sujet de certains médicaments ou autres technologies de la santé ne signifie d'aucune manière que l'ACMTS endosse l'utilisation de ces technologies.

### Le trouble dépressif majeur et les troubles anxieux

- Addressing Psychological Trauma Due to the COVID-19 Pandemic: Can Technology Help in a Time of Acute Crisis? (*Webinaire*, juin 2020)
- Programmes de TCCi offerts au Canada pour le trouble dépressif caractérisé et les troubles anxieux (*Outil*, avr. 2020)
- Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis (*Examen des technologies*, févr. 2020)
- Internet-Delivered, Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders (*Projet sur l'utilisation optimale*, mars 2019)
- Psychotherapy and Pharmacotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Rapid Qualitative Review (*Synthèse accompagnée d'une évaluation critique*, mars 2020)
- Pharmacogenomic Testing in Depression: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (*Synthèse accompagnée d'une évaluation critique*, févr. 2020)

### Trouble de stress posttraumatique

- Trouble de stress posttraumatique : Résumé des preuves sur l'efficacité (*Outil*, avr. 2018)
- Internet-Based Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder (*Projet sur l'utilisation optimale*, janv. 2020)

### Trouble psychiatrique

- Clozapine Initiation for Schizophrenia: A Review of Clinical Effectiveness and Guidelines (*Synthèse accompagnée d'une évaluation critique*, févr. 2020)
- Ketamine for Pharmacological Management of Aggression and Agitation in Pre-Hospital Settings: A Review of Comparative Clinical Effectiveness, Safety, and Guidelines (*Synthèse accompagnée d'une évaluation critique*, mai 2019)
- Clonidine for the Treatment of Psychiatric Conditions and Symptoms: A Review of Clinical Effectiveness, Safety, and Guidelines (*Synthèse accompagnée d'une évaluation critique*, févr. 2018)
- Virtual Health Care for Adults With Schizophrenia and/or Psychosis: Clinical Effectiveness and Guidelines (*Compilation de références*, sept. 2020)

### Divers

- Dialectical Behaviour Therapy for People With Borderline Personality Disorder: A Rapid Qualitative Review (*Synthèse accompagnée d'une évaluation critique*, nov. 2020)
- Lurasidone Hydrochloride for Bipolar Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (*Synthèse accompagnée d'une évaluation critique*, févr. 2020)
- Patient Navigation Programs for People With Dementia: Clinical Utility, Cost-Effectiveness, and Guidelines (*Synthèse de résumés*, déc. 2020)
- Peer Support For Youth Mental Health: Clinical Effectiveness and Guidelines (*Compilation de références*, janv. 2021)

L'ACMTS est un organisme indépendant sans but lucratif dont le mandat est de fournir aux décideurs du système de santé canadien des preuves objectives leur permettant de prendre des décisions éclairées concernant l'usage optimal des médicaments, des dispositifs médicaux et des procédures cliniques au sein de notre système de santé.

L'ACMTS reçoit du financement des gouvernements fédéral, provinciaux et territoriaux, à l'exception du Québec.